• Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and secured US FDA priority review acceptance for its new drug application, with a decision scheduled for late September 2026.
• This combination of encouraging data in an ultra-rare indication and accelerated regulatory review could meaningfully broaden Mirum’s rare disease portfolio beyond its existing commercial assets.
• We’ll now examine how the FDA’s priority review for zilurgisertib may reshape Mirum’s rare-disease investment narrative and future growth mix.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Mirum Pharmaceuticals Investment Narrative Recap

To own Mirum, you need to believe its rare disease franchise can justify heavy R&D spend and persistent losses as it matures. The FDA priority review for zilurgisertib adds a meaningful near term catalyst, but it does not remove the core risk around revenue concentration in Livmarli and exposure to pricing and reimbursement pressure.

Among recent updates, the VISTAS Phase 2b data for volixibat in primary sclerosing cholangitis stands out. Together with the zilurgisertib filing, it reinforces a near term catalyst cluster across multiple indications while Mirum is still posting large net losses (US$798.8 million in the most recent period) and investing heavily to support future launches.

Yet behind the promising FOP data, investors still need to weigh the risk that concentrated rare disease revenues and pricing pressure could...

Mirum Pharmaceuticals' narrative projects $1.1 billion revenue and $234.1 million earnings by 2029. This requires 25.9% yearly revenue growth and a $1,032.9 million earnings increase from -$798.8 million today.

Uncover how Mirum Pharmaceuticals' forecasts yield a $144.15 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already projecting about US$1.3 billion of revenue and US$436.2 million of earnings by 2029, which is far more aggressive than consensus and assumes Mirum’s concentrated rare disease bets pay off despite regulatory and pricing risks; this new FOP milestone could either support that view or prompt you to reassess how confident you really are in those kinds of assumptions.

Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth 8% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.